/RNA
Avidity Biosciences, Inc.
RNA • NASDAQRNA • NASDAQ • Healthcare
$13.91-4.40%-0.64
$13.91-4.40%(-0.64)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
83Low Risk
Momentum
26Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
77.9%▼22.1pp
Revenue after COGS
Operating
-3977.3%▼499.9pp
After operating expenses
Net
-3650.4%▼692.7pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
-14.5
Price vs earnings
EV/EBITDA
-14.2
Enterprise value
FCF Yield
-6.7%
Cash generation
Earnings Yield
-6.9%
Inverse of P/E
Capital Efficiency
-40
GoAI Quality ScorePoor
ROEReturn on Equity
-40.5%Weak
ROAReturn on Assets
-35.0%Weak
ROICReturn on Invested Capital
-42.2%Weak
Financial Health
Current RatioHealthy
9.20
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.42x
Debt repayment capacity (<3x)
Income QualityFair
0.95
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $18.75M | $10.90M | $9.56M | $9.22M | $9.33M |
| Gross Profit | $14.60M | $10.90M | $7.46M | $7.84M | -$91.86M |
| Gross Margin | 77.9% | 100.0% | 78.0% | 85.0% | -984.9% |
| Operating Income | -$745.94M | -$378.94M | -$235.60M | -$178.91M | -$118.05M |
| Net Income | -$684.63M | -$322.30M | -$212.22M | -$174.00M | -$118.01M |
| Net Margin | -3650.4% | -2957.7% | -2219.9% | -1886.3% | -1265.4% |
| EPS | -$4.97 | -$2.89 | -$2.91 | -$3.34 | -$2.85 |
Average Price Target
$72.00▲ 417.6% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Avidity Biosciences, Inc., the average price target is $72.00, with a high forecast of $72.00 and a low forecast of $72.00. The average price target represents a 417.6% increase from the current price of $13.91.
Highest
$72.00
Average
$72.00
Lowest
$72.00
Rating Distribution
Strong Buy
0
0%
Buy
10
50%
Hold
10
50%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Chardan Capital● Maintain
Neutral
2025-11-11TD Cowen▼ Downgrade
Buy→Hold
2025-10-29Chardan Capital▼ Downgrade
Buy→Neutral
2025-10-28RBC Capital▼ Downgrade
Outperform→Sector Perform
2025-10-28Leerink Partners▼ Downgrade
Outperform→Market Perform
2025-10-27HC Wainwright & Co.▼ Downgrade
Buy→Neutral
2025-10-27Raymond James▼ Downgrade
Strong Buy→Market Perform
2025-10-27Citigroup▼ Downgrade
Buy→Neutral
2025-10-27Bernstein▼ Downgrade
Outperform→Market Perform
2025-10-27Needham▼ Downgrade
Buy→Hold
2025-10-27Earnings History & Surprises
BEAT RATE
44%
Last 18 quarters
AVG SURPRISE
-3.1%
EPS vs Estimate
BEATS / MISSES
8/10
Last 18 quarters
LATEST EPS
$-1.59
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
-20.5%
$-1.59 vs $-1.32
Q4 '25
-16.5%
$-1.27 vs $-1.09
Q3 '25
-27.4%
$-1.21 vs $-0.95
Q2 '25
-2.3%
$-0.90 vs $-0.88
Q1 '25
-5.3%
$-0.80 vs $-0.76
Q4 '24
+8.5%
$-0.65 vs $-0.71
Q3 '24
+14.5%
$-0.65 vs $-0.76
Q2 '24
+2.5%
$-0.79 vs $-0.81
Q1 '24
-46.3%
$-0.79 vs $-0.54
Q4 '23
+6.6%
$-0.71 vs $-0.76
Q3 '23
+21.4%
$-0.66 vs $-0.84
Q2 '23
+17.8%
$-0.74 vs $-0.90
No investor questions available.
Latest News
No news available